OverviewSuggest Edit
Celyad is a biopharmaceutical company, specialized in cell therapy and developing of technologies to treat severe diseases with poor prognosis. The Company focuses on immuno oncology, cardiology, and medical devices.
| Type | Public | |
| Founded | 2007 | |
| HQ | Mont-Saint-Guibert, BE | Map |
| Website | celyad.com | |
| Employee Ratings | More |
Recent NewsAll News
- Celyad Oncology Announces September 2021 Conferences Schedule
- Celyad Oncology to Announce First Half 2021 Financial Results and Host Conference Call
- Celyad Oncology Presents Preliminary Data from Phase 1 IMMUNICY-1 Trial of shRNA-based Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma at the European Hematology Association Virtual Congress
- Celyad Oncology Announces June 2021 Conference Schedule
Key People/Management at Celyad
Michel Lussier
Chairman, Non-Executive Director
Filippo Petti
Chief Executive Officer/CFO
Frederic Lehmann
VP Clinical Development and Medical Affairs
Philippe Dechamps
Chief Legal Officer
Philippe Nobels
VP Human Resources
Marina Udier
Independent Director
Celyad Office Locations
Celyad has offices in Mont-Saint-Guibert and New York
Mont-Saint-Guibert, BE (HQ)
2 Rue Edouard Belin
New York, NY, US
60 Broad St Suite 3502
Celyad Financials and Metrics
Celyad Revenue
Celyad's revenue was reported to be €3.54 m in FY, 2017 which is a 58.5% decrease from the previous period.
| EUR | |
|---|---|
Revenue (FY, 2017) | 3.5m |
Revenue growth (FY, 2016 - FY, 2017), % | (58.5%) |
Gross profit (FY, 2017) | 3.0m |
Gross profit margin (FY, 2017), % | 85.5% |
Net income (FY, 2017) | (56.4m) |
EBIT (FY, 2017) | (52.9m) |
Market capitalization (9-Sept-2021) | 59.0m |
Closing stock price (9-Sept-2021) | 4.0 |
Cash (31-Dec-2017) | 23.3m |
EV | 36.3m |
Celyad's current market capitalization is €59 m.
| EUR | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|
Cash | 100.2m | 48.4m | 23.3m |
Accounts Receivable | 549.0k | 1.4m | 233.0k |
Current Assets | 109.4m | 85.4m | 36.4m |
PP&E | 1.1m | 3.6m | 3.3m |
| EUR | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|
Net Income | (29.1m) | (23.6m) | (56.4m) |
Depreciation and Amortization | 273.0k | 760.0k | 966.0k |
Accounts Payable | 1.1m | (740.0k) | (2.5m) |
Cash From Operating Activities | (27.3m) | (24.7m) | (44.4m) |
| EUR | FY, 2015 |
|---|---|
Financial Leverage | 1.4 x |
Celyad Cybersecurity Score
Celyad Online and Social Media Presence
2.38k Twitter followers
Celyad has 2.38k Twitter Followers. The number of followers has increased 0.3% month over month and increased 0.7% quarter over quarter
Celyad's Trends
Twitter Engagement Stats for @CelyadSA
747
Tweets
651
Following
2.4k
Followers
13
Tweets last 30 days
2.4
Avg. likes per Tweet
92.3%
Tweets with engagement
Celyad News and Updates
September 01, 2021
Celyad Oncology Announces September 2021 Conferences Schedule
MONT-SAINT-GUIBERT, Belgium, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company plans…
July 29, 2021
Celyad Oncology to Announce First Half 2021 Financial Results and Host Conference Call
MONT-SAINT-GUIBERT, Belgium, July 29, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company will r…
June 11, 2021
Celyad Oncology Presents Preliminary Data from Phase 1 IMMUNICY-1 Trial of shRNA-based Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma at the European Hematology Association Virtual Congress
MONT-SAINT-GUIBERT, Belgium, June 11, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced preliminary data from t…
May 26, 2021
Celyad Oncology Announces June 2021 Conference Schedule
MONT-SAINT-GUIBERT, Belgium, May 26, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the company plans t…
May 17, 2021
Global Stem Cell Therapy Market Report 2021-2030 Featuring Anterogen, JCR Pharma, Medipost, Osiris Therapeutics, Pharmicell, Astellas Pharma, Cellectis, Celyad, Novadip Biosciences, and Gamida Cell
Dublin, May 17, 2021 (GLOBE NEWSWIRE) -- The "Stem Cell Therapy Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering. Stem Cell Therapy Global Market Report 2021: COVID-19 Growth And Change To 2030 provides the strategists, marke…
March 18, 2021
Celyad Oncology to Announce Full Year 2020 Financial Results and Host Conference Call
MONT-SAINT-GUIBERT, Belgium, March 18, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company will …
Celyad Blogs
September 01, 2021
Celyad Oncology announces September 2021 Conference Schedule
Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development
The post Celyad Oncology announces September 2021 Conference Schedule appeared first on Celyad Oncology.
August 04, 2021
Celyad Oncology Reports First Half 2021 Financial Results and Recent Business Highlights
Enrollment continues at dose level three in Phase 1 IMMUNICY-1 trial evaluating CYAD-211 in relapsed/refractory multiple myeloma (r/r MM); next
The post Celyad Oncology Reports First Half 2021 Financial Results and Recent Business Highlights appeared first on Celyad Oncology.
July 20, 2021
Celyad Oncology Presents Updates on Allogeneic CAR T Clinical Candidates and shRNA-based Preclinical Concepts at Research & Development Day
Phase 1 IMMUNICY-1 trial evaluating CYAD-211 in relapsed/refractory multiple myeloma (r/r MM) showed dose dependent engraftment up to dose level
The post Celyad Oncology Presents Updates on Allogeneic CAR T Clinical Candidates and shRNA-based Preclinical Concepts at Research & Development Day ap…
July 13, 2021
Celyad Oncology to Host Virtual Research & Development Webinar on July 20th
Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development
The post Celyad Oncology to Host Virtual Research & Development Webinar on July 20th appeared first on Celyad Oncology.
July 07, 2021
Celyad ONcology to Participate at the William Blair Biotech Focus Conference 2021
Mont-Saint-Guibert, Belgium – Celyad ONcology SA ( Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and
The post Celyad ONcology to Participate at the William Blair Biotech Focus Conference 2021 appeared first on Celyad Oncology.
May 19, 2021
Transparency Notification received from Victory Capital Management Inc. (Article 14 §1 of the Law of 2 May 2007)
Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development
The post Transparency Notification received from Victory Capital Management Inc. (Article 14 §1 of the Law of 2 May 2007) appeared first on …
Celyad Frequently Asked Questions
When was Celyad founded?
Celyad was founded in 2007.
Who are Celyad key executives?
Celyad's key executives are Michel Lussier, Filippo Petti and Frederic Lehmann.
How many employees does Celyad have?
Celyad has 87 employees.
What is Celyad revenue?
Latest Celyad annual revenue is €3.5 m.
What is Celyad revenue per employee?
Latest Celyad revenue per employee is €40.7 k.
Who are Celyad competitors?
Competitors of Celyad include Bellicum Pharmaceuticals, Alnylam Pharmaceuticals and Sorrento Therapeutics.
Where is Celyad headquarters?
Celyad headquarters is located at 2 Rue Edouard Belin, Mont-Saint-Guibert.
Where are Celyad offices?
Celyad has offices in Mont-Saint-Guibert and New York.
How many offices does Celyad have?
Celyad has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies